参考文献/References:
[1] Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer, 2005, 12(2):245-262.
[2] Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 2009. 94(5):1612-1617.
[3] Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endoer Relat Cancer, 2008, 15(1):191-205.
[4] Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancaer. J clin Endocrinol Metab, 2005, 90(12):6373-6379.
[5] Lupi C, Giannini R, Ugolini C, et al. Association of BRAFV600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007, 92(1):4085-4090.
[6] 郝丽君,方军初,洪智慧,等.99mTcO4核素显像联合超声检查对甲状腺结节的鉴别诊断价值.中华医学杂志,2011,91(45):3210-3213.
[7] Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J of Surg, 2003, 186(6):702-709.
[8] Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens:a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6):2867-2872.
[9] Cradic KW, Milosevic D, Rosenberg AM, et al. Mutant BRAFn799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab, 2009, 94(12):5001-5009.
[10] Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone:malysis of 5,768 patients with average 10-year follow-up[J/OL]. World J Surg, 2012[2012-01-22]. http://www.springerlink,com/content/w642210502436521.[published online ahead of print July 20, 2012].
[11] Namba H,Nakashima M,Hayashi T,et al.Clinical implication of hot spof BRAF mufaHon,V600E,in papillary liiyroid cancers.J Clin Endocrinol Metab,2003,88(9):4393-4397.
[12] Barollo S.Pennelli G,Vianello F,et al.BRAF in primary and recurrent papillary thyroid canuers:the relationship with 131I and 2-[18F] fluoro-2-deoxy-D-glucose uptake ability.Fur J Endocrinol,2010,163(4):659-663.
[13] Riesco-Eizaguirre G,Rodríguez I,De la Vieja A,et al.The BRAFV600E oncogene induces transforming growth factor beta secre-tion leading to sodium iodide symporter repression and increased malignancy in tkyroid cancer.Cancer Res,2009,69 (21):8317-8325.
[14] Feine U,Lietzenmayer R,Ilanke JP,et al.Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.J Nucl Med,37 (9):1468-1472.
[15] Gupta-Abramson V,Troxel AB,Nellore A,et al.Phase II trial of sorafenib in advanced thyroid cancer.J Clin Oncol,2008,26(29):4714-4719.
[16] Kloos RT,Ringel MD,Knopp MV,et al.Phase II trial of sorafenib in metastatic thyroid cancer.J Clin Oncol,2009,27 (10):1675-1684.
[17] Hahn O,Stadler W.Sorafenib,Curr Opin Oncol,2006,18 (6):615-621.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]